Aptus Capital Advisors LLC Buys Shares of 3,083 DexCom, Inc. (NASDAQ:DXCM)

Aptus Capital Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 3,083 shares of the medical device company's stock, valued at approximately $240,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Nordea Investment Management AB boosted its stake in shares of DexCom by 2.8% in the fourth quarter. Nordea Investment Management AB now owns 80,590 shares of the medical device company's stock valued at $6,271,000 after purchasing an additional 2,183 shares during the period. First Hawaiian Bank boosted its position in DexCom by 556.1% in the 4th quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock valued at $1,801,000 after buying an additional 19,629 shares during the period. Watts Gwilliam & Co. LLC purchased a new position in DexCom in the 4th quarter valued at approximately $3,334,000. Czech National Bank grew its stake in shares of DexCom by 3.7% in the fourth quarter. Czech National Bank now owns 84,689 shares of the medical device company's stock worth $6,586,000 after acquiring an additional 3,057 shares in the last quarter. Finally, Capital Investment Advisors LLC purchased a new stake in shares of DexCom during the fourth quarter worth $206,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Performance

Shares of DXCM stock traded down $0.68 during midday trading on Friday, hitting $84.66. The company had a trading volume of 3,348,982 shares, compared to its average volume of 4,331,690. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $132.26. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company's 50 day simple moving average is $71.08 and its 200 day simple moving average is $77.20. The stock has a market cap of $33.20 billion, a price-to-earnings ratio of 59.20, a PEG ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. The business's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 earnings per share. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. This trade represents a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock worth $4,734,384 over the last 90 days. Company insiders own 0.32% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Mizuho assumed coverage on DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective for the company. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Robert W. Baird dropped their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus target price of $98.11.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.